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ABSTRACT
Introduction Patient experience of nursing care is 
correlated with safety, clinical effectiveness, care 
quality, treatment outcomes and service use. Effective 
nursing care includes actions to develop nurse–patient 
relationships and deliver physical and psychosocial care to 
patients. The high risk of transmission of the SARS- CoV-2 
virus compromises nursing care. No evidence- based 
nursing guidelines exist for patients infected with SARS- 
CoV-2, leading to potential variations in patient experience, 
outcomes, quality and costs.
Methods and analysis we aim to recruit 840 in- patient 
participants treated for infection with the SARS- CoV-2 
virus from 14 UK hospitals, to a cluster randomised 
controlled trial, with embedded process and economic 
evaluations, of care as usual and a fundamental nursing 
care protocol addressing specific areas of physical, 
relational and psychosocial nursing care where potential 
variation may occur, compared with care as usual. Our 
coprimary outcomes are patient- reported experience 
(Quality from the Patients’ Perspective; Relational Aspects 
of Care Questionnaire); secondary outcomes include 
care quality (pressure injuries, falls, medication errors); 
functional ability (Barthell Index); treatment outcomes 
(WHO Clinical Progression Scale); depression Patient 
Health Questionnaire-2 (PHQ-2), anxiety General Anxiety 
Disorder-2 (GAD-2), health utility (EQ5D) and nurse- 
reported outcomes (Measure of Moral Distress for Health 
Care Professionals). For our primary analysis, we will 
use a standard generalised linear mixed- effect model 
adjusting for ethnicity of the patient sample and research 
intensity at cluster level. We will also undertake a planned 
subgroup analysis to compare the impact of patient- level 
ethnicity on our primary and secondary outcomes and will 
undertake process and economic evaluations.
Ethics and dissemination Research governance and 
ethical approvals are from the UK National Health Service 
Health Research Authority Research Ethics Service. 
Dissemination will be open access through peer- reviewed 
scientific journals, study website, press and online 
Strengths and limitations of this study
 ► This study is the first randomised controlled trial of 
a fundamental care clinical nursing protocol for pa-
tients infected with the SARS- CoV-2 virus.
 ► The intervention relates specifically to patients with 
the SARS- CoV-2 virus admitted to inpatient wards 
who are not invasively ventilated.
 ► The intervention programme theory will enable gen-
eralisation of our findings to other environments 
such as care homes, patients with other conditions 
requiring isolation, and global health systems.
 ► The trial coprimary outcomes require patient partic-
ipants to have capacity to consent and report their 
experience of care, and, therefore, we will be unable 
to collect and report data from patients who lack this 
capacity.
 ► In common with other cluster randomised controlled 
trials of behaviour change interventions, we are un-
able to blind nurses, participants or data collectors 
to trial arm allocation
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media, including free online training materials on the Open University’s 
FutureLearn web platform.
Trial registration number ISRCTN13177364; Pre-results.
BACKGROUND
Patient experience of nursing care is correlated with safety, 
clinical effectiveness, care quality, treatment outcomes 
including mortality and overall service use.1–7 Nursing 
care is a key determinant of patient experience8 9 and 
satisfaction.10 Effective nursing care includes the estab-
lishment of compassionate nurse–patient relationships 
known as ‘relational nursing care’ in order to facilitate 
the physical and psychosocial care work undertaken by 
nurses to meet the fundamental care needs of patients 
such as nutrition, hydration, skin integrity, personal care, 
mobility, hygiene, breathing, elimination and mental 
well- being.11 12
Measuring patient experience is analogous to collecting 
a patient- reported outcome measure (PROM)13 in that 
both are ‘a measurement based on a report that comes directly 
from the patient (ie, study subject)’.14 However, whereas a 
PROM captures ‘the status of a patient’s health condition 
without amendment or interpretation of the patient’s response 
by a clinician or anyone else’,14 a patient- reported experience 
measure (PREM) is a measure of a patient’s perception 
of their personal experience of the healthcare they have 
received.15 Two PREMs for evaluating patients’ experi-
ences of nursing have been developed and tested; the 
Relational Aspects of Care Questionnaire—RACQ)8 16 
and the Quality from the patient’s perspective—QPP.17 18
The combination of COVID-19 symptoms and high risk 
of transmission of the SARS- CoV-2 virus poses unique chal-
lenges for physical, psychosocial and relational nursing 
care. Previously, the 2003 SARS outbreak demonstrated 
that nurses’ ability to provide compassionate fundamental 
care was compromised: ‘The establishment/maintenance of 
therapeutic nurse- client relationship required additional time 
given the barriers of mask, gloves and gowns. p419 ‘Restrictions 
on visitors were difficult for staff because family members are 
usually involved in the social, psychological and, to some extent, 
physical care of patients’. p620 ‘Interaction time decreased, and 
patients began to feel more abandoned’. p2821
During the development of our trial protocol described 
below, we found no international evidence- based guide-
lines for nursing hospitalised patients with the SARS- CoV-2 
virus, the majority of whom are not invasively mechani-
cally ventilated. This leads to the potential for variations 
in patient experience, treatment outcomes, care quality 
and costs, as reported by nurses who responded to our 
survey, also described below. Although individual nurses, 
teams and organisations reported rapidly adapting their 
procedures to nurse these patients, compared with 
usual nursing care, we as yet do not know how to opti-
mise nursing care for the specific challenges of nursing 
patients with COVID-19, including mitigating the impact 
of wearing personal protective equipment (PPE), nor 
how effective these adaptations are in terms of these 
important outcomes.
Between July and October 2020, we developed a clin-
ical nursing protocol. We undertook a rapid review22 
of published literature to identify the evidence for the 
effectiveness of, and barriers to, fundamental nursing 
care procedures in patients with the SARS- CoV-2 virus or 
other conditions requiring isolation, in terms of overall 
patient experience, care quality, functional ability and 
treatment outcomes—PROSPERO registration number: 
CRD4202020091.23 We also ran a UK- wide survey of 
nurses and nonregistered care staff working with hospi-
talised patients with the SARS- CoV-2 virus who were not 
invasively ventilated to identify respondents’ views on 
‘missed care’,24 25 barriers to care and innovation strate-
gies respondents had adapted to meet the fundamental 
care needs of such patient. We obtained research gover-
nance approval from the Health Research Authority 
(IRAS project ID: 287288, protocol number 1920/31) and 
ethical approval from the University of Exeter research 
ethics committee (no: 20/07/256) for this survey. We 
then convened three consensus development panels26–28 
of nurses, and patients with experience of hospitalisa-
tion with the SARS- CoV-2 virus, to agree the content and 
design of the clinical nursing protocol. We will report the 
results of our systematic review and survey elsewhere.
In the COVID- NURSE trial, our objectives are: (a) to 
compare care as usual and an evidence- based nursing 
protocol for patients with the SARS- CoV-2 virus against 
care as usual, in terms of patients’ reported experience 
of transactional and relational nursing care, care quality, 
treatment outcomes and costs and (b) to compare the 
effects of using the clinical protocol on nurses’ moral 
distress
METHODS: PARTICIPANTS, INTERVENTIONS AND OUTCOMES
Design
We will undertake a cluster randomised controlled supe-
riority trial29 30 with embedded iterative process31 and 
economic evaluations32 between 02 November 2020 and 
18 October 2021). Our initial funded, approved and 
registered design was a rapid- cycle cluster randomised 
controlled trial33 with three review ‘waves’. Like adaptive 
trial designs, rapid cycle trials embed a priori opportuni-
ties into trial designs to enable review and minor adap-
tions to interventions between waves. We also planned to 
pair match 18 trial sites according to two variables with a 
potential impact on outcomes: (1) ethnicity, where being 
of black, Asian and minority ethnicity (BAME) increases 
the risk of SARS- COV-2 infection compared with white 
individuals and where people of Asian ethnicity may be 
at higher risk of intensive care unit (ICU) admission and 
death34 and (2) research intensity which is associated 
with improved hospital outcomes.35 We planned to clas-
sify ethnicity according to the latest census data for the 
local authority in which a hospital is located (low (<68%) 
vs medium (68% to 74%) vs high (>74%) non- BAME 
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categories based around an overall mean of 71% non- 
BAME admissions. We planned to classify research inten-
sity according to two categories: research intensive versus 
not research intensive, where research intensive is defined 
as ≥0.1 unique recruiting studies in the 2019–2020 Q4 
open data from National Institute for Health Research 
(NIHR) divided by number of inpatient elective admis-
sions in January–March 2020, and nonresearch intensive 
is <0.1.
Since submitting this protocol for peer review by 
this journal, experience enrolling wave 1 sites during 
October–January 2021 taught us that our ideal situation is 
subjected to considerable stress as sites adapt to a rapidly 
changing situation on the ground, facing significant clin-
ical and research pressures. Although we successfully 
recruited three pairs (six sites) of sites matched as above 
for our planned first wave during October–December 
2020, operational difficulties caused by (a) the trial not 
being prioritised for National Health Service (NHS) 
research infrastructure resources and (b) the impact of 
the second wave of the SARS- COV-2 virus on nursing sick-
ness levels, led to very significant delays to site opening. 
Our six wave one sites were unable to start data collec-
tion concurrently, delaying our planned wave 1 review. 
Furthermore, we recruited several other sites for waves 2 
and 3 for which we could not find a match on the variables 
listed above. These issues threatened to prevent us from 
recruiting to time and target within the funded period 
(July 2020–April 2021). Therefore, in order for the trial to 
recruit sufficient sites and participants and for us to retain 
our ability to review and make minor amendments to the 
intervention in response to process data on fidelity and 
acceptability, we amended the design to a simple cluster 
randomised trial, with an embedded iterative process eval-
uation. As a consequence, as part of the statistical analysis 
plan, we will also adjust for ethnicity of the patient sample 
at cluster level and, where patient outcomes are tested, 
at patient level rather than prerandomisation. Finally, 
we revised our sample size calculations, see below and 
obtained additional funding to continue the trial for a 
further 6 months from the previous planned end date of 
18 April 2021. We began data collection on 18 January 
2021 and plan to continue until the end of August 2021.
Setting
We will recruit 14 UK district- general and teaching hospital 
NHS Trusts (clusters). Participants will be recruited from 
one or more wards at each site where patients are being 
treated for infection with the SARS- COV-2 virus.
Participant eligibility criteria
Patients who are not invasively ventilated, aged ≥18 years, 
currently hospitalised and being treated for infection 
with the SARS- CoV-2 virus or recently discharged after 
such treatment and who have received nursing care for a 
minimum of 72 hours during their admission; registered 
nurses and nursing care workers working under the super-
vision of registered nurses caring for patients hospitalised 
and treated for infection with the SARS- CoV-2 virus. Partic-
ipants must be able to give informed consent (online 
supplemental appendices 1 and 2). We will provide trans-
lation facilities for participants unable to understand and 
speak English. We will recruit participants specifically 
from wards allocated to the care of patients admitted for 
treatment of COVID-19 symptoms.
Interventions
Experimental intervention
Care as usual and the clinical protocol developed as 
described above.
In order to preserve intervention blinding across trial 
control sites, we have not included the full clinical guide-
line here. To do so would potentially unblind nurses 
working in control cluster sites. Although it is an ethical 
principle to make a full intervention protocol available for 
peer and reader scrutiny, there is a competing and equal 
ethical principle to preserve control cluster integrity and 
prevent contamination of control sites. This ensures that 
all participants in a trial contribute their data to a study 
that is neither compromised nor subjected to significant 
potential biases. Trials with compromised blinding are 
often rejected in systematic reviews or lead to uncertain 
conclusions. Below is a summary, therefore. However, 
we commit to making all written and online materials 
available to the scientific and clinical community free 
of charge at the conclusion of the trial, to include a free 
to access Massive Online Open Course supporting the 
intervention. In the interim, we will refuse no reasonable 
request to view our guideline, having assured ourselves 
that a request will not compromise intervention blinding.
The protocol consists of four elements adapted from 
the methods used successfully in a previous cluster 
randomised controlled trial to significantly increase 
handwashing by nurses and care staff36: a guideline, 
trigger reminder posters, staff education programme and 
leadership from ward managers and senior nurses.
The clinical guideline consists of 26 potential strategies 
that can be used by nurses to address barriers to phys-
ical, relational and psychosocial nursing care identified 
in our survey and systematic review. In our survey,37 eight 
barriers were ranked within the top five in at least one 
component of the three physical, relational and psycho-
social care areas. These were wearing PPE, the severity of 
patients’ conditions, inability to take items in and out of 
isolation rooms without donning and doffing PPE, lack 
of time to spend with patients, lack of presence from 
specialised services, for example, physiotherapists, lack of 
knowledge about COVID-19, insufficient stock and reluc-
tance to spend time with patients for fear of catching the 
SARS- CoV-2 virus.
From this data, we grouped the guideline strategies 
thematically into actions which address: (a) communi-
cation with patients, with patients’ significant others, 
between patients and their significant others, between 
nurses and between nurses and other members of the 
care team, (b) the organisation of fundamental nursing 
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care activities, (c) addressing the values of patients and 
their significant others, (d) delivering specific funda-
mental nursing care interventions, (e) identifying and 
responding to the mental health and well- being needs of 
patients’ and their significant others.
The trigger posters contain key information on these 
same strategies to remind nurses to use them. The online 
educational resource includes video testimony from 
patients, carers, nurses and scientists about these same 
care activities and is hosted on the Open University’s 
‘FutureLearn’ platform.38 Finally, the guideline includes 
advice to managers on organising care teams, educating 
and supporting members of their nursing teams, infor-
mation on this also delivered via the ‘FutureLearn’ 
platform.38
We will monitor clinical protocol fidelity and accept-
ability as part of our process evaluation and modify our 
guideline, educational and leadership strategies iter-
atively, making minor adjustments to these elements 
according to findings from our process evaluation quan-
titative and qualitative data. We will embed any changes 
to the protocol in the subsequent experimental interven-
tion sites.
Control
Care as usual only. We will record staffing staff skill mix 
details alongside a description of clinical nursing proce-
dures and organisation in place in the usual care clusters.
Outcomes
We will collect participant- level outcome data. Our copri-
mary outcomes will be patient reported experience of 
transactional nursing care using the QPP17 18 and rela-
tional nursing care using the RACQ.8 16 Our secondary 
outcomes will include: measures of quality of care (pres-
sure injuries, falls, medication errors) collected by the 
UK National Health Service Ward to Board dashboard39; 
functional ability by the Barthel Index40 41; treatment 
outcomes by the WHO Clinical Progression Scale42; 
depression by the PHQ-2,43 anxiety by the GAD-2,44 health 
utility by the EQ5D45 and nurse outcomes by the Measure 
of Moral Distress for Health Care Professionals.46 47
Participant timeline
We will undertake the trial during 50 weeks of interven-
tion and rolling data collection, with data collected from 
patient participants admitted for treatment of SARS- CoV-2 
infection and staff caring for them.
Target sample size
Using published formulae by Hayes and Moulton,16 we 
calculated our patient participant sample size based on 
an estimate of the minimum clinically important differ-
ence for the QPP of 0.2 and the typical within- unit stan-
dard deviation (0.6), supplied by the measure developers 
and an intraclass correlation coefficient (ICC) of 0.02. 
We have examined a number of potential scenarios, 
taking into account different cluster sizes and different 
between- cluster SD values informed by between- country 
differences on measures, estimated to provide 90% and 
80% power. Based on conversations about feasibility with 
NHS clinical leaders, with a cluster size of 60 the trial 
would generate over 80% power with six clusters per arm 
and 90% power with seven clusters in each arm. However, 
because power calculations in cluster trials with a small 
number of clusters can be especially sensitive to the 
approximation used for df, we used a range of alternative 
approaches (no small sample adjustment, Satterthwaite 
approximation and Kenward- Rogers approximation; 
cluster- level linear regression) to explore the robustness 
of the sample size calculations. While these tended to esti-
mate reduced power at each number of clusters compared 
with a formula- based power calculation, an estimate 
of 14 clusters (7 per arm) generated power of greater 
than 80% in every case. This number of clusters is fairly 
robust to number of patients per cluster. Even assuming 
under- recruitment leading to 50 patients per site, power 
is maintained at greater than 80%. Therefore, we will aim 
to recruit 840 patient participants. Although we have not 
powered the sample size on nurse participant outcomes, 
in consultation with clinical colleagues in our investi-
gator and advisory groups, we anticipate that around 50 
registered nurses and healthcare support workers will be 
involved in the direct care of these patient participants 
leading to a recruitment target of 700 registered nurse 
and nursing care worker participants, including student 
nurses.
Recruitment
We will recruit cluster sites via the NHS chief nurse and 
clinical research networks. We will monitor available data 
from Public Health England on case and hospitalisation 
rates by NHS Trust in order to identify recruitment sites 
where there are sufficient potential participants. We will 
use these data to prepare sites for involvement. Clinical 
research nurses will recruit patient participants from 
admitted patients according to the eligibility criteria 
above.
Allocation
We will randomly allocate sites to the intervention and 
control groups by an unblinded statistician who has no 
role in site recruitment or data analysis to ensure allo-
cation concealment; only the unblinded statistician will 
have access to the allocation list. Randomisation will 
use a static blocked list through the use of an externally 
administered, password- protected randomisation website 
independently developed and maintained by the United 
Kingdom Clinical Research Collaboration (UKCRC)- 
registered University of Exeter Clinical Trials Unit 
(ExeCTU).
Data collection
We will collect outcome data from patient participants 
after they have received nursing care for a minimum of 
72 hours, either during their admission or a maximum 
of 2 weeks postdischarge. All outcome measures will be 
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applied to all participants equally and collected by clinical 
research nurses and other good clinical practice48 trained 
research staff, who will also obtain consent. It will not be 
possible to blind research nurses, clinicians or patient 
participants to allocation, although control group cluster 
sites will be blind to the intervention as described earlier. 
Statistical analysts will be blind to group allocation when 
receiving data to analyse. We will collect outcome data 
either face to face, by video/audio technology or by post 
following discharge according to the infection control 
procedures in place and participant preference. We will 
collect outcome data from nurses either face to face in 
their hospital or over the phone, according to their pref-
erence. Site level Ward to Board data will be collected from 
routine hospital statistics.
Data management
Participants will be identified by a unique study ID. 
Personal identifiable data, including date of birth and 
NHS number, may be collected but will be stored sepa-
rately to research data and will be destroyed as per appli-
cable regulations when the project is concluded. Data 
will be managed by ExeCTU following General Data 
Protection Regulation (GDPR) and data protection 
guidelines and all relevant Clinical Trial Regulations. 
All data will be anonymised prior to publication. Data 
will be collected and stored electronically in accordance 
with the Data Protection Act 2018 and ICH GCP E6 R2. 
ExeCTU will use Redcap Cloud Electronic Data Capture 
System to collect all case report data. This system is vali-
dated to ISO27001 standards, backed up and maintained 
in Europe. This system is fully compliant to GDPR regu-
lations and managed by ExeCTU. Any additional study 
data will be stored and backed up on the secure ExeCTU 
servers and maintained by ExeCTU. Data will be cleaned 
and validated appropriately, and a full Data Protection 
Impact Assessment will be undertaken along with the 
development of a comprehensive Data Management Plan 
before the first participant is recruited.
Where data are disseminated (eg, via report, presen-
tation or publication), they will be anonymised. We will 
align all confidentiality and data handling with the Cald-
icott principles.49 Anonymised data will be stored indefi-
nitely on a research data storage system provided by the 
University of Exeter called Open access Research Exeter 
for archiving (http://www. exeter. ac. uk/ research/ open-
research/ policies/ ore/).
Statistical data analysis
We will analyse numerical data in Stata V.16.50 Our 
primary analysis for patient and nurse outcomes will use 
a standard generalised linear mixed- effect model with 
appropriate small- sample adjustment to account for the 
small number of clusters, and adjusting for ethnicity of 
the patient sample at cluster level and, where patient 
outcomes are tested, at patient level as well. Sensitivity 
analyses for patient and nurse outcomes will use variance- 
weighted cluster- level summaries with adjustment for 
ethnicity based on 2011 census and hospital postcode 
and for research intensity. Analysis of hospital outcomes 
will use rate ratios. Second, and focusing on patient- level 
outcomes, we will estimate intervention effectiveness in 
an exploratory analysis. This analysis will use generalised 
linear mixed- effects models to model time trends. Anal-
ysis will include time from implementation, reflecting 
growing adaptation and expertise, as well as calendar 
time, reflecting the course of the COVID-19 epidemic. 
We will also undertake a planned subgroup analysis to 
compare the impact of patient- level ethnicity on our 
primary and secondary outcomes.
Missing data
Data are collected from patients and nurses at one time 
point. As a result, missingness is likely to be at item- level 
within scales and at scale level. Where >50% of items in a 
scale are completed (including ‘not applicable’ or ‘don’t 
know’ responses), a scale score will be generated by either 
taking the average of remaining items (all QPP subscales, 
RAC- Q-14, MMD- HP) or by rescaling sum scores to the 
full range (Barthel Index). This is an appropriate strategy 
when factor loadings are homogeneous and reliability for 
scales is good.51 Observations from single- item or two- 
item scales (WHO Clinical Progression Scale, PHQ-2, 
GAD-2) will be dropped from the analysis.
Process evaluation
We will evaluate the impact of nurses’ and nursing care 
workers’ fidelity to the clinical protocol, intervention 
mechanisms and context of care delivery on outcomes 
using: a bespoke instrument for capturing fidelity to 
reflect the protocol components; the Culture of Care 
Barometer Questionnaire52; the NoMAD instrument 
for measuring implementation readiness and accept-
ability53 54; contextual data on patient acuity, staffing 
ratios, nurses/care staff education levels, seniority and 
year of qualification and other contextual variables. We 
will conduct interim analyses of process evaluation data 
on fidelity to the protocol and protocol utilisation to 
evaluate intervention component fidelity and implemen-
tation. We will subsequently amend the clinical protocol 
based on this data before embedding the new protocol in 
intervention sites.
We will conduct semistructured qualitative interviews 
with a purposive sample of nurses and care staff, using 
a topic guide derived from the content of the clinical 
protocol and our analysis of quantitative data, to explore 
their views on the mechanisms, impact and acceptability 
of the clinical protocol. This method will enable us to 
investigate the meaning of participants’ responses, both 
exploring views on our predefined topics of interest and 
eliciting more detail on any emerging themes.55 Inter-
views will be conducted using telephone or online audio- 
conference methods, unless face to face interviews are 
risk assessed as being safe and are preferred by partici-
pants. With participants’ consent (online supplemental 
appendices 1 and 2), we will audio- record interviews and 
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transcribe interviews verbatim. We will use NVivo1056 to 
organise the data and analyse data using Framework anal-
ysis to allow for the combination of inductive and deduc-
tive approaches in our development of themes.57 We will 
use joint displays58 to integrate the qualitative data with 
the quantitative outcome data in a mixed- methods anal-
ysis59 to explore and explain variation in the outcome 
data. We will use this data to refine an intervention 
programme theory60 61 incorporating context, mecha-
nisms and fidelity.31
Economic evaluation
We will conduct within trial cost- effectiveness analysis by 
adopting the NHS perspective with the main outcome 
measure the quality- adjusted life year (QALY) derived 
from the EQ- 5D- 5L.32 45 We will apply the NICE threshold 
of £20 000 per QALY. Cost data will include staff training, 
length of stay, including ICU costs and COVID-19- specific 
interventions from baseline to discharge using a bespoke 
hospital care use inventory. We will apply unit costs derived 
from national sources including Personal Social Services 
Research Unit62 and NHS Reference Costs.63 Nonpara-
metric bootstrapping will be used to quantify uncer-
tainty. We will present outputs as ICERs, cost- effectiveness 
acceptability curves and expected net benefit.
Monitoring
Day to day management of the trial and study will be by 
the chief- investigator, other coinvestigators and a research 
manager. We will set up an independent combined Trial 
Steering and Data Monitoring Committee (TSC/DMC)48 
and a patient and public involvement group.64 We will 
undertake a risk assessment of the trial and produce a 
monitoring plan that will be commensurate with the risk 
identified to particularly ensure that we have input from 
people of colour, including from Black, Asian and other 
minority ethnic groups, who are at greater risk from infec-
tion with the SARS- CoV-2 virus.
Safety reports of serious adverse events
Given this trial is not a clinical trial of an investigational 
medicinal product (CTIMP), the recording and reporting 
of non- serious adverse events (SAEs) is not required,65 
since, although likely to be common in the target popu-
lation, they are unlikely to be related to either the inter-
vention or trial participation. Likewise, by nature of the 
patient participants’ clinical condition, we will expect 
some SAEs, specifically death or prolongation of hospital 
stay,65 but that these will be both expected and unlikely 
to be related to intervention or trial procedures. As all 
non- CTIMP research is required to adhere to the prin-
ciples of good clinical practice,48 66 it was nonetheless 
agreed with the trial sponsor, research ethics committee 
(Health Research Authority, North East—Newcastle & 
North Tyneside 2 Research Ethics Committee, reference: 
20/NE/0253) and independent TSC/DMC to record 
and review each SAE by the CI on a case- by- case basis to 
determine if it is related to the trial intervention or proce-
dures. This process is overseen by the TSC/DMC.
Patient and public involvement
The proposed study has been informed by ongoing collab-
orations between patients, clinicians and researchers, 
including in a previous NIHR- funded project ESSEn-
tial Nursing CarE (ESSENCE) on fundamental nursing 
care.67 A version of the lay summary was reviewed by six 
members of the ‘Peninsula Patient Involvement Group’, 
giving feedback on the broad idea of the research as well 
as specific points on the clarity of the summary. A patient 
coapplicant has been involved with the development of 
the proposal. We will ensure that there is a patient voice 
in all discussions and decisions and will ensure the inte-
gration of broader PPI activity in these decisions. We have 
worked with a wider group of patients with experience 
of hospitalisation for COVID-19 symptoms to inform the 
coproduction of the nursing protocol, development of all 
patient facing materials, finalising the nursing protocol 
for rapid- cycle testing, adaptions to the nursing protocol 
after each cycle of testing, dissemination of findings, 
including the production of an online training module 
for nurses on the FutureLearn platform. The involvement 
of patients will be informed by what is possible within the 
ongoing pandemic and to suit the situation of interested 
patients. Involvement will be flexible and responsive to 
their needs. We will adopt high standards of equality, 
diversity and inclusivity68 throughout.
Ethical issues
We will conduct this trial in such a way as to protect the 
human rights and dignity of the participants, as reflected 
in the Helsinki Declaration.69 We have obtained gover-
nance and ethical approval from the Health Research 
Authority National Research Ethics Service (IRAS project 
ID 288479; REC reference: 20/NE/0253). Participants 
will not receive any financial inducement to participate. 
We will invite eligible patients and nurses to participate 
in data collection and will only collect data from partic-
ipants who individually consent. Participants may with-
draw from the study at any time without prejudicing 
their treatment, care or employment. We will conform to 
Good Clinical Practice Guidelines, data protection and 
freedom of information acts. We prospectively registered 
the trial with the ISRCTN registry on 9 September 2020, 
before our intended data collection start date. We have 
registered protocol amendments when required.
Outputs and dissemination
We will disseminate our results through publication in 
peer- reviewed scientific journals, our study website and 
other press and online media. Manuscript authors will 
be those considered to have made a substantive intel-
lectual contribution to the study. The investigators and 
relevant authorities will have access to the trial dataset. 
Furthermore, we will store anonymised research data 
and outputs in the University of Exeter’s Open Research 
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Exeter repository (https:// ore. exeter. ac. uk/ repository/) 
in order to facilitate open access to, and the impact of, 
our research.
The main output from this study will be evidence on 
whether our COVID-19- specific clinical nursing care 
protocol delivers additional benefits in overall patient 
experience, care quality, functional ability and treatment 
outcomes, with cost- effectiveness estimates, for hospi-
talised patients with the SARS- CoV-2 virus not invasively 
ventilated, compared with care as usual in hospital wards. 
We will have a programme theory allowing us to poten-
tially generalise any such benefits to environments like 
care homes, patients with other conditions requiring 
isolation and to global health systems. If effective, our 
guidelines, education materials and strategies will be 
made accessible via Health Education England, the Open 
University’s FutureLearn38 web platform and through 
experienced NHS sites acting as training and dissemina-
tion hubs for other health Trusts, environments such as 
care homes and global health systems.
DISCUSSION
The strengths of this study include that it is the first 
randomised controlled trial of a fundamental care clin-
ical nursing protocol for patients infected with the 
SARS- CoV-2 virus and the intervention relates specifically 
to these patients admitted to inpatient wards who are 
not invasively ventilated. Our intervention programme 
theory will enable generalisation of our findings to other 
environments such as care homes, patients with other 
conditions requiring isolation and global health systems. 
In terms of limitations, the trial coprimary outcomes 
require patient participants to have capacity to consent 
and report their experience of care, and, therefore, we 
will be unable to collect and report data from patients 
who lack this capacity. In common with other cluster 
randomised controlled trials of behaviour change inter-
ventions, we are unable to blind nurses, participants or 
data collectors to trial arm allocation.
Our research aligns with the WHO COVID-19 R&D 
Roadmap priorities and research gaps,70 viz: ‘to deter-
mine optimal clinical practice strategies to improve the 
processes of care’. It includes ‘rapid approaches to capture 
healthcare worker views (surveys, interviews)’ and a rapid 
ethnograph(y) in healthcare’.70 It will, therefore, provide 
guidance to nurses attempting to overcome significant 
barriers to providing fundamental physical, relational and 
psychosocial care to patients, specifically those with the 
SARS- CoV-2 virus not invasively ventilated but with a gener-
alisable programme theory suitable for adaptation to other 
care environments, other pandemics and other nations 
globally.
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